



For Immediate Release

**CyGenics Granted Key Patent for the China Market
Patent provides for extensive licensing opportunities in China**

21st MARCH 2005 - Leading adult stem cell biotechnology and immunotherapy company, CyGenics, Ltd. (ASX: CYN) announced that it has been granted a patent in China for its immune T cell production technology.

This patent adds to the company's extensive worldwide intellectual property. It also protects one of the company's leading technologies in a key emerging market. The Chinese biotech industry was estimated at 200 million yuan (US\$24 million) in 1986, and grew rapidly to 200 billion yuan (US\$24 billion) by 2003. The issued patent will pave the way for the licensing of the company's patented three dimensional cell growth devices within this large and growing market. CyGenics expects to initiate such licensing discussions with the aim of receiving up front fees and milestone payments from partners in return for application and territory specific licences. This patent will run until 2019.

The patent will assist in the company's ongoing productisation of its core technologies. Cell Sciences, a wholly owned subsidiary of CyGenics, markets a range of these three-dimensional cell growth devices. Cytomatrix, another wholly owned subsidiary, has made use of the same technology to provide vaccine screening services, most notably to the US Department of Defense.

"We are pleased to have received this patent grant," said Chris Fullerton, Chairman, CyGenics. "This patent will allow for more products as well as licensing opportunities, adding



additional momentum to the group's existing and growing revenues."

About CyGenics

CyGenics is a biotechnology and immunotherapy company focused on the development and commercialisation of adult stem cell-related products, services, applications and technologies. From its headquarters in Australia, CyGenics operates three divisions: Singapore-based CordLife (tissue banking services, in particular, cord blood banking) and Cell Sciences (consumable cell culture products), and Cytomatrix (cell therapeutics and technology development) based in the USA. CyGenics is listed on the Australian Stock Exchange, under the symbol CYN. For more information, please visit www.cygenics.com.

For more information, please contact:

Ronald Hee	Rod Nockles
Corporate Communication Director	
Marketing Manager	Financial & Corporate Re
CordLife Pte Ltd	Level 20,
600 North Bridge Road,	114 William Street
#12-09/10, Parkview Squ	Melbourne Victoria 3000
Singapore 188778, Singa	Australia
Tel : +65 6238 0808	Tel: +61 3 9670 7996
Fax : +65 6295 1108	Fax: +61 3 9670 3883
Mobile: +65 9061 9098	Mobile: +61 (0) 419 691
Email: rhee@cordlife.cc	E-mail: r.nockles@fcr.cc